H Izzedine1, B Billemont, F Thibault, O Rixe. Show Affiliations » 1. Department of Medical Oncology, AP-HP, Pitie-Salpetriere Hospital, Paris, France.
Abstract
Entities: Chemical Disease
Mesh： See more » Antineoplastic Agents/therapeutic useCarcinoma, Renal Cell/drug therapyCarcinoma, Renal Cell/pathologyClinical Trials as TopicForecastingHumansIndoles/therapeutic useKidney Neoplasms/drug therapyKidney Neoplasms/pathologyProtein-Tyrosine Kinases/antagonists & inhibitorsPyrroles/therapeutic useReceptors, Vascular Endothelial Growth Factor/antagonists & inhibitorsSunitinibTreatment Outcome
Substances： See more » Antineoplastic AgentsIndolesPyrrolesProtein-Tyrosine KinasesReceptors, Vascular Endothelial Growth FactorSunitinib
Year: 2007 PMID： 17631600 DOI： 10.1093/annonc/mdm298
Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976